



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-1979393

European Medicines Agency decision

EMA/PE/0000232771

of 21 March 2025

on the agreement of a paediatric investigation plan and on the granting of a waiver for tacrolimus in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

EMA/PE/0000232771

of 21/03/2025

on the agreement of a paediatric investigation plan and on the granting of a waiver for tacrolimus in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Laboratoires Théa on 19 April 2024 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 January 2025, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the on the agreement of a paediatric investigation plan and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation for tacrolimus, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for tacrolimus, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Laboratoires Théa, 12 Rue Louis Bleriot, 63100 – Clermont-Ferrand, France.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-1775656

Amsterdam, 31 January 2025

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMA/PE/0000232771

Scope of the application

Active substance(s):

Tacrolimus

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of vernal keratoconjunctivitis

Pharmaceutical form(s):

Eye drops, suspension

Route(s) of administration:

Ocular use

Name/corporate name of the PIP applicant:

Laboratoires Théa

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Laboratoires Théa submitted for agreement to the European Medicines Agency on 19 April 2024 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 27 May 2024.

Supplementary information was provided by the applicant on 21 October 2024. The applicant proposed modifications to the paediatric investigation plan.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of vernal keratoconjunctivitis

The waiver applies to:

- the paediatric population from birth to less than 4 years of age;
- eye drops, suspension, ocular use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of vernal keratoconjunctivitis

2.1.1. Indication(s) targeted by the PIP

Treatment of moderate to severe vernal keratoconjunctivitis (VKC) in children from 4 years of age

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 4 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Eye drops, suspension

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	<p>Study 1 (T1695-3724-06)</p> <p>To evaluate the <i>in vitro</i> phototoxicity of tacrolimus in 3T3 fibroblasts using the neutral red uptake assay</p> <p>Study 2 (T1695-3624-03)</p> <p>Preliminary 14-day ocular tolerance in rabbit to evaluate the ocular tolerance of tacrolimus</p> <p>Study 3 (T1695-2224-05)</p> <p>Evaluation of pharmacokinetic profile of tacrolimus in rabbit compared to active control in cornea, conjunctivae, lens,</p>

	<p>aqueous humour and whole blood following a single and multiple ocular topical administration</p> <p>Study 4 (T1695-3624-04)</p> <p>Evaluation of 3-month ocular tolerance and systemic exposure through repeated daily ocular topical administrations of tacrolimus in albino rabbits during 3-month, followed by a 2-week recovery period</p>
Clinical studies	<p>Study 5 (LT1695-201)</p> <p>Randomised, investigator-masked, active-controlled trial to evaluate efficacy and safety of tacrolimus eye drops compared to ciclosporin ophthalmic emulsion in children from 4 years to less than 18 years of age with moderate to severe VKC</p> <p>Study 6 (LT1695-301)</p> <p>Randomised trial to evaluate efficacy and safety of tacrolimus eye drops in children from 4 years to less than 18 years of age with moderate to severe VKC</p>
Modelling and simulation analyses	Not applicable
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2029
Deferral for one or more measures contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.